Form 4: Director Clyde Hosein Receives RSU Grant at Dentsply Sirona

Dentsply Sirona Director Clyde Hosein was granted 22,822 restricted stock units as part of an equity compensation arrangement.

Summary

• Director Clyde Hosein acquired 22,822 restricted stock units (RSUs) in Dentsply Sirona Inc. (XRAY).
• The transaction occurred on June 3, 2026.
• The RSUs were granted at a price of $0, representing equity-based compensation.
• Following this transaction, the director's total beneficial ownership increased to 64,075.456 shares of common stock.
• The RSUs are scheduled to vest in full one year from the date of the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Increase in total beneficial ownership by a member of the board.

Negatives

• None identified; this is a standard equity grant for a director.

Risks

• Standard market risks associated with equity ownership in Dentsply Sirona Inc.

Future Outlook

The RSUs vest in full one year from the date of grant, June 3, 2026.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to incentivize long-term performance and align board interests with those of public shareholders.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for S&P 500 and mid-cap healthcare companies.
• Vesting periods of one year are common for annual director equity awards in the medical device sector.

Stakeholder Impact

• Shareholders may view the increased equity stake of a director as a positive sign of confidence in the company's long-term trajectory.

Next Steps

• Vesting of the 22,822 RSUs on June 3, 2027.

Key Dates

Keywords

Dentsply Sirona, XRAY, Form 4, Insider Trading, Director Compensation, Restricted Stock Units